The FDA's strategic pivot towards accelerated review for in vivo gene editing therapies isn't just a bureaucratic tweak; it's a seismic shift, potentially slashing development timelines by 30% and de-risking investments in a sector poised to reach a $5 trillion valuation by 2040. This regulatory clarity, particularly for life-altering conditions like sickle cell disease, is transforming scientific breakthroughs into tangible market opportunities at an unprecedented pace.
The human genome, a vast, intricate instruction manual, has long been the ultimate black box. For decades, medicine grappled with the symptoms of genetic misprints, patching up problems with varying degrees of success. But what if we could edit the manual itself? Not just correct a typo on a single page, but rewrite entire flawed chapters directly within the body’s living library. This isn't science fiction; it’s the burgeoning reality of in vivo gene editing, and the U.S. Food and Drug Administration (FDA) is now actively paving a superhighway for these revolutionary therapies to reach patients.
This isn't merely about faster approvals; it's about a fundamental re-evaluation of how we bring transformative medicine to market. The FDA, often perceived as a glacial gatekeeper, is demonstrating a remarkable agility, recognizing that the potential to cure previously intractable diseases warrants a more dynamic, collaborative approach. This shift isn't just good news for patients; it's a tectonic plate movement for the biotech investment landscape, creating unprecedented opportunities for those who understand the new regulatory topography.
Consider the sheer audacity of the endeavor: delivering molecular scalpels and genetic repair kits directly into cells, correcting errors with pinpoint precision, all while the patient goes about their daily life. This leap from ex vivo (outside the body) to in vivo (inside the body) therapies dramatically expands accessibility and reduces the logistical burdens that have historically plagued gene therapy. The FDA’s proactive stance, offering clearer guidance and potentially expedited review pathways, acts as a powerful de-risking agent for companies navigating this complex, high-stakes frontier.
The biological clock of innovation rarely ticks louder than in the realm of gene editing. We've moved beyond the theoretical, past the proof-of-concept, and are now firmly in the era of therapeutic application. The market for gene therapies, once a niche corner of biotech, is rapidly expanding, propelled by a growing understanding of genetic diseases and the increasingly sophisticated tools available to address them. This isn't just about treating symptoms; it's about eradicating the root cause, a paradigm shift that promises to redefine medicine as we know it.
The global sickle cell disease (SCD) market serves as a compelling microcosm of this larger trend. Valued at approximately $1.5 billion in 2023, it's projected to surge past $7 billion by 2032. This isn't organic growth from existing treatments; it's a direct consequence of the arrival of gene therapies. While ex vivo therapies like Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy and bluebird bio's (BLUE) Lyfgenia have already secured FDA approval in late 2023, their logistical complexities – requiring cell extraction, modification, and reinfusion – limit their reach. The true prize, the holy grail, lies in in vivo gene editing, which promises a less invasive, more scalable solution.
High logistical barriers → Limited patient access → Constrained market penetration → Suboptimal patient outcomes.
The transition to in vivo approaches is not merely an incremental improvement; it's a quantum leap in terms of patient accessibility and market potential. Imagine a therapy that doesn't require weeks in a specialized hospital, bone marrow transplants, or the inherent risks of ex vivo manipulation. This is the promise of in vivo base editing: a single, potentially curative treatment delivered directly to the patient, correcting the genetic mutation where it lives. The FDA's recognition of this potential, manifest in their "streamlined review process" guidance, is a critical accelerant. This guidance signals a regulatory environment that is not just receptive but actively supportive of therapies demonstrating significant clinical benefit and safety in early trials, effectively shortening the runway from lab bench to bedside.
This regulatory clarity is a beacon for investment, transforming what was once a high-risk, long-horizon bet into a more palatable proposition. Companies that can successfully navigate this expedited pathway stand to capture significant market share and command premium pricing, given the transformative nature of these cures. The potential for $2-3 million per dose pricing, already seen with existing gene therapies, underscores the immense financial upside for successful platforms. The total market for SCD gene therapies alone could exceed $10 billion annually if these in vivo approaches prove safe, effective, and broadly adopted, representing a compelling shift from managing a chronic condition to offering a definitive cure.
At the heart of the in vivo gene editing revolution lies a suite of molecular tools, each a marvel of biological engineering. While CRISPR-Cas9 grabbed headlines for its ability to cut and paste DNA, the next generation, base editing, offers a more refined approach: changing a single "letter" of the genetic code without breaking the DNA double helix. Think of it as using a precise eraser and pencil rather than a pair of scissors and glue. This distinction is crucial, as it significantly reduces the potential for unintended genomic alterations, a major safety concern with earlier CRISPR iterations.
Beam Therapeutics (BEAM) stands at the forefront of this base editing frontier. Their BEAM-101 program for sickle cell disease exemplifies the elegance of this technology. Instead of inducing double-strand breaks, which can lead to unpredictable outcomes, BEAM-101 aims to convert a specific adenine base to guanine, correcting the single-point mutation responsible for SCD directly within hematopoietic stem cells. This is achieved by delivering a base editor complex via a lipid nanoparticle (LNP), a delivery mechanism that has proven its mettle with mRNA vaccines. The LNP acts as a microscopic mail carrier, ensuring the genetic repair machinery reaches its intended cellular address.
The beauty of in vivo delivery is its potential to overcome the logistical and patient burden associated with ex vivo therapies. With ex vivo approaches, patients undergo apheresis to collect their stem cells, followed by a conditioning regimen (often chemotherapy) to make space in their bone marrow, then reinfusion of the modified cells. It's a grueling process, limiting access to specialized centers and excluding many patients who are too frail for the procedure. In contrast, an in vivo therapy could involve a single intravenous infusion, transforming the treatment from a complex medical odyssey into a more manageable outpatient procedure.
Other players are also pushing the boundaries of in vivo gene editing. Verve Therapeutics (VERV), for instance, is applying base editing to cardiovascular diseases, aiming to permanently lower cholesterol by editing genes like PCSK9 in the liver. Their platform, while focused on a different indication, highlights the versatility and broad applicability of in vivo base editing. Similarly, Intellia Therapeutics (NTLA), known for its in vivo CRISPR therapies for transthyretin amyloidosis, is demonstrating the power of delivering CRISPR components directly to target organs, showcasing the potential for a wide array of genetic conditions.
The FDA's guidance on these therapies is a testament to the growing maturity and safety profile of these platforms. By providing clarity on trial design, endpoints, and manufacturing requirements, the agency is not just reacting to innovation; it's actively shaping its trajectory. This proactive regulatory stance helps de-risk the colossal investment required for drug development, giving companies a clearer roadmap and investors greater confidence in the eventual market entry. The promise is not just therapeutic; it's economic, with the potential for multi-billion dollar market opportunities for each successfully developed in vivo therapy.
The implications of a streamlined regulatory pathway for in vivo gene editing therapies extend far beyond the immediate beneficiaries. This isn't just about a few rare diseases; it's about unlocking a multi-trillion-dollar market that could fundamentally alter the healthcare landscape. The ability to correct genetic errors within the body, efficiently and safely, opens the door to treating a vast array of conditions, from common metabolic disorders to complex neurological diseases, that were once considered beyond therapeutic reach.
The global gene therapy market, currently a rapidly expanding segment, is poised for exponential growth. While specific projections vary, conservative estimates place the market size for gene therapies well over $50 billion by 2030, with in vivo approaches expected to capture an increasingly dominant share. However, when we consider the full spectrum of diseases that could be addressed – from the 1.5 million people globally living with sickle cell disease to the millions more suffering from other monogenic disorders and even polygenic conditions – the total addressable market easily enters the trillions. This isn't hyperbole; it's the logical conclusion of a technology capable of offering definitive cures rather than chronic management.
The economic ripple effect will be profound. For healthcare systems, the initial high cost of these therapies ($2-3 million per dose) must be weighed against the lifetime costs of managing chronic diseases, which can run into the tens of millions per patient. A single curative treatment, even at a high price point, can represent a net saving over decades. This economic calculus is a powerful driver for payers to embrace these innovations, particularly as the long-term efficacy and safety profiles mature.
Moreover, the regulatory clarity provided by the FDA acts as a powerful magnet for capital. Investors, traditionally wary of the protracted timelines and unpredictable outcomes of biotech development, now have a clearer line of sight to market. This reduces the "valley of death" for early-stage biotechs, where promising science often founders due to lack of funding. With a more predictable regulatory path, venture capital and institutional investors are more likely to support the audacious science that underpins these therapies.
The market implications also extend to the broader pharmaceutical industry. Established players are actively seeking partnerships, acquisitions, and licensing deals to gain access to cutting-edge gene editing platforms. This creates a vibrant ecosystem of innovation, where small, nimble biotechs can develop breakthrough technologies, and larger pharmaceutical companies can leverage their manufacturing, distribution, and commercialization muscle to bring these therapies to a global patient population. The competition for these transformative assets is intensifying, driving up valuations and creating significant opportunities for early investors.
Key Takeaway: The FDA's accelerated pathways are transforming in vivo gene editing from a scientific curiosity into a multi-trillion-dollar investment opportunity, driven by expanded patient access and a compelling economic value proposition for healthcare systems.
The race to master in vivo gene editing is a high-stakes marathon, attracting a diverse field of contenders, each bringing unique strengths to the genetic arena. From established biotech giants to nimble startups, the competitive landscape is a vibrant tapestry of innovation, collaboration, and intense rivalry. Understanding these players is key to navigating the investment opportunities emerging from this transformative field.
Beam Therapeutics (BEAM) is arguably the most prominent player in the in vivo base editing space, particularly for sickle cell disease. Their BEAM-101 program is a flagship initiative, demonstrating the power of their proprietary base editing platform. In late 2024, Beam announced promising preliminary data from its BEACON and ASCENT clinical trials for BEAM-101, showcasing initial engraftment and allele editing in treated patients. This early success is critical, laying the groundwork for more mature data expected in 2025, which could further accelerate its path towards pivotal trials and eventual market entry. The company's strategic focus on base editing, with its enhanced precision and reduced off-target effects compared to traditional CRISPR, positions it as a leader in the next generation of gene editing.
Verve Therapeutics (VERV), while not directly targeting sickle cell, is a crucial player due to its focus on in vivo gene editing for cardiovascular diseases. Their approach to permanently lower LDL cholesterol by editing the PCSK9 gene in the liver using base editing highlights the broad applicability of these platforms. Their progress validates the in vivo delivery mechanisms and base editing technology, creating positive read-throughs for other companies in the space. The success of Verve's platform could unlock a massive market for common diseases, further solidifying the investment thesis for in vivo gene editing.
Intellia Therapeutics (NTLA) has already demonstrated clinical success with its in vivo CRISPR therapies, notably for transthyretin amyloidosis. Their experience navigating the regulatory landscape for in vivo delivery of genetic material provides invaluable insights and validation for the entire sector. While their primary focus has been on CRISPR-Cas9, their expertise in LNP delivery and in vivo targeting is highly relevant to the broader gene editing ecosystem.
Editas Medicine (EDIT) is another key contender in the CRISPR space, also developing in vivo therapies. While they have faced some clinical challenges, their foundational intellectual property and ongoing research contribute significantly to the competitive dynamic. The collective efforts of these companies are not just about individual drug development; they are about validating an entire therapeutic modality.
The competitive landscape is further shaped by the existing ex vivo therapies like Casgevy and Lyfgenia. While these have established a market, their logistical hurdles create a clear opening for less invasive in vivo alternatives. The race is on not just to cure, but to cure more efficiently and accessibly.
| Company | Ticker | Key Sector | Market Cap {.num-cell} | Signal |
|---|---|---|---|---|
| Beam Therapeutics | BEAM | In Vivo Base Editing | $4.5B | BULLISH |
| Verve Therapeutics | VERV | In Vivo Base Editing (Cardio) | $2.8B | WATCH |
| Intellia Therapeutics | NTLA | In Vivo CRISPR | $5.1B | NEUTRAL |
| Editas Medicine | EDIT | In Vivo CRISPR | $1.2B | WATCH |
| Vertex Pharmaceuticals | VRTX | Ex Vivo Gene Therapy | $110B | NEUTRAL |
| CRISPR Therapeutics | CRSP | Ex Vivo Gene Therapy | $6.7B | NEUTRAL |
Key Takeaway: Beam Therapeutics holds a leading position in the in vivo base editing race for sickle cell disease, with Verve Therapeutics validating the broader platform for other indications, creating a compelling investment narrative.
The investment thesis for in vivo gene editing, particularly under the FDA's new, streamlined regulatory regime, is compellingly simple: early access to curative therapies will command premium pricing and capture vast, underserved markets. This isn't merely about incremental improvements; it's about a fundamental redefinition of disease management, shifting from chronic care to one-time, definitive cures. For investors, this translates into opportunities for outsized returns, provided they can identify the platforms and players best positioned to execute.
The bull case rests on several pillars. First, the unmet medical need for many genetic diseases is immense. Conditions like sickle cell disease, hemophilia, and various metabolic disorders impose enormous burdens on patients and healthcare systems. A curative therapy, even at a high price point, offers significant long-term value. Second, the technological sophistication of base editing, with its enhanced precision and reduced off-target effects, addresses key safety concerns that have historically plagued gene therapy. This improved safety profile is critical for regulatory approval and broader patient adoption.
Third, the FDA's proactive stance is a game-changer. By providing clearer guidance and potentially expedited review processes, the agency is effectively shortening the time to market and reducing the regulatory uncertainty that often depresses biotech valuations. This de-risking of the development pathway makes the sector far more attractive to investors. Finally, the scalability of in vivo delivery compared to ex vivo approaches promises to expand the addressable patient population dramatically, transforming niche markets into multi-billion-dollar opportunities.
However, a balanced perspective requires acknowledging the bear case. The primary concern revolves around unforeseen long-term safety issues. While base editing is designed to be more precise, the long-term effects of permanent genomic alteration are still being studied. Off-target editing, even at low frequencies, could lead to adverse events years down the line. Manufacturing complexities and the high cost of goods for these highly specialized therapies also present challenges, potentially limiting broad access and reimbursement. Furthermore, the competitive landscape is intense, and a single clinical setback for one company could cast a shadow over the entire modality.
My conviction level for in vivo gene editing is HIGH. The scientific progress, coupled with the regulatory tailwinds, creates a unique confluence of factors. The potential for curative treatments for devastating diseases offers both immense societal benefit and significant financial reward. The key is to invest in companies with robust platforms, strong intellectual property, and experienced management teams capable of navigating both the scientific and regulatory hurdles.
LONG BEAM — Beam Therapeutics is a leader in in vivo base editing for SCD, with promising early clinical data and a platform that addresses key safety concerns of earlier gene editing technologies. SHORT BLUE — Bluebird Bio faces significant commercialization challenges and intense competition from more advanced in vivo therapies, despite its ex vivo approvals. WATCH FDA Guidance Updates — Continued clarity and expansion of accelerated pathways will signal further de-risking and market maturation for the entire sector.
Even with the FDA rolling out the red carpet, the path for in vivo gene editing therapies is not without its treacherous turns. The very nature of altering the human genome, even with surgical precision, introduces a unique set of challenges and risks that investors must meticulously evaluate. This isn't just about clinical efficacy; it's about the long shadow cast by unintended consequences and the logistical hurdles of bringing truly revolutionary medicine to scale.
The most significant risk remains long-term safety. While base editing is designed to be highly specific, the possibility of off-target editing – unintended changes to the genome – cannot be entirely eliminated. The human body is an incredibly complex system, and even minor, seemingly innocuous changes could manifest as adverse events years or even decades after treatment. Immunogenicity, the body's immune response to the viral vectors (like AAVs or LNPs) used to deliver the gene editing machinery, is another persistent concern. An immune reaction could neutralize the therapy, reduce its efficacy, or trigger dangerous inflammatory responses.
Manufacturing and scalability present formidable logistical challenges. Producing these highly complex biological therapies at commercial scale, ensuring consistent quality, purity, and potency, is a monumental task. The specialized facilities, stringent quality control, and intricate supply chains required contribute significantly to the high cost of goods, which in turn impacts pricing and reimbursement strategies. A bottleneck in manufacturing could severely limit market penetration, even for a highly effective therapy.
Reimbursement and access are also critical hurdles. With price tags in the millions, securing broad insurance coverage and ensuring equitable patient access will be an ongoing battle. While the long-term economic benefits of a cure are clear, the upfront cost can be prohibitive for payers. Innovative payment models, such as outcomes-based agreements or annuities, are being explored, but their widespread adoption is still nascent. Moreover, the global reach of these therapies will be constrained by varying regulatory frameworks and healthcare infrastructure in different countries.
The competitive landscape itself poses a risk. While the market is vast, the number of companies vying for a slice of the gene editing pie is growing. A clinical failure by one prominent player could trigger a sector-wide sell-off, regardless of the individual merits of other companies' platforms. Furthermore, the rapid pace of scientific discovery means that today's cutting-edge technology could be superseded by an even more advanced approach tomorrow, creating a constant need for innovation and adaptation.
Finally, ethical considerations surrounding germline editing (changes that can be inherited) and the potential for "designer babies" loom large, though current therapeutic efforts are focused on somatic cells (non-heritable changes). While regulators and companies are acutely aware of these boundaries, public perception and ethical debates could influence policy and investment, creating an unpredictable external factor. Navigating this minefield requires not just scientific prowess but also astute strategic foresight and robust risk management.
For the astute investor, the FDA's streamlined pathway for in vivo gene editing therapies isn't just a news item; it's an unambiguous investment signal. This regulatory shift is a powerful de-risking event, shortening time horizons and clarifying the path to market for what are arguably the most transformative medicines of our generation. Strategic allocation in this sector demands a nuanced understanding of both the science and the market dynamics.
The core of the investment angle lies in identifying companies with proprietary gene editing platforms that demonstrate superior safety and efficacy profiles, particularly those employing base editing or prime editing for enhanced precision. These platforms represent the foundational intellectual property that will drive future therapeutic pipelines. Look for companies with strong preclinical data, clear mechanistic understanding, and a robust clinical trial strategy that aligns with the FDA's expedited pathways.
Sector-specific ETFs offer a diversified entry point for investors seeking broad exposure to the gene editing revolution without picking individual winners. ETFs focused on genomics, biotechnology, or even specific gene therapy segments can provide a basket of companies, mitigating single-stock risk while capturing the overall growth trajectory of the sector. However, for those seeking alpha, a more concentrated approach targeting specific companies with leading platforms and promising clinical assets is warranted.
Consider companies like Beam Therapeutics (BEAM), which is not only leading in sickle cell disease but also exploring other indications, demonstrating the versatility of its platform. Their early clinical data, combined with the FDA's supportive environment, paints a compelling picture. Similarly, Verve Therapeutics (VERV), with its focus on common cardiovascular diseases, represents a massive addressable market if its in vivo base editing approach proves successful. These companies are not just developing drugs; they are building the biological infrastructure for a new era of medicine.
Tactical recommendations include:
The investment landscape is shifting from a speculative long shot to a calculated bet on the future of human health. The FDA's push is not just a nudge; it's a powerful gravitational pull for capital towards this transformative sector.
The FDA's strategic embrace of streamlined pathways for in vivo gene editing therapies isn't merely a bureaucratic footnote; it's the unmistakable clarion call for a new era of curative medicine. We are witnessing the foundational shift from managing chronic diseases to eradicating them, a transition that will redefine healthcare and create unprecedented investment opportunities over the next two decades. The market, once a cautious observer, is now being actively invited to participate in this genetic renaissance.
The next 2-5 years will be critical. We expect to see pivotal clinical trial data from leading in vivo gene editing programs, particularly in sickle cell disease, which will serve as a powerful validation for the entire modality. Regulatory approvals for these first-in-class in vivo therapies are highly probable within this timeframe, triggering significant market re-ratings for the successful pioneers. Beyond 2030, the applications will expand exponentially, moving from rare monogenic disorders to more common conditions like cardiovascular disease and neurodegenerative disorders, pushing the total market valuation for gene editing well into the trillions of dollars.
This is not a fleeting trend; it's a fundamental re-architecture of biological possibility. The ability to precisely edit the human genome within the body, coupled with a supportive regulatory environment, positions this sector as one of the most compelling long-term growth stories in modern finance. The early movers, those who can successfully translate scientific breakthroughs into safe, effective, and scalable therapies, will not only reap immense financial rewards but also leave an indelible mark on human history.
LONG BEAM — For its leading base editing platform and promising clinical trajectory in a high-value indication. SHORT traditional symptomatic treatments for genetic diseases — As curative gene therapies gain traction, the market for palliative care will inevitably shrink. WATCH next-generation delivery systems — Innovations in non-viral delivery will unlock even broader applications and enhance safety profiles.
Are we on the cusp of truly editing disease out of existence, and are you positioned to capitalize on this genetic revolution?
The FDA's streamlined pathway for in vivo gene editing therapies is poised to be a seismic shift in the biotech landscape, accelerating development and de-risking market entry for companies at the forefront of this technology. This regulatory clarity is a green light for innovation, but it will undoubtedly create winners and losers. The distinction often lies in a company's technological approach and its existing market position. Investors, buckle up; the gene editing race just got a whole lot more interesting.
Beam Therapeutics (NASDAQ: BEAM) is perfectly positioned to capitalize on this streamlined in vivo pathway. With a market capitalization of approximately $2.70 billion as of July 2026, Beam is a leader in base editing, a more precise form of gene editing that chemically modifies a single base in DNA or RNA without cutting the double helix. This precision minimizes off-target edits, a significant safety concern for traditional CRISPR-Cas9 approaches.
Beam's competitive advantage lies in its robust pipeline of in vivo base editing programs, particularly BEAM-101 for sickle cell disease (SCD). Promising preliminary data from its BEACON and ASCENT clinical trials for BEAM-101 in late 2024 showed initial engraftment and allele editing, paving the way for further clinical progression. The company expects to submit a Biologics License Application (BLA) for BEAM-101 as early as year-end 2026. This accelerated regulatory path, facilitated by the FDA's guidance, means Beam could bring a potentially transformative, less invasive treatment to market faster than previously anticipated. Their strong cash position of $1.2 billion as of March 31, 2026, provides a runway into mid-2029, supporting their ambitious development plans.
Investment Thesis: Investors should consider BEAM for its differentiated base editing technology, which offers superior precision and potentially a better safety profile for in vivo applications. The FDA's streamlined pathway significantly de-risks their development timeline, especially for BEAM-101, which targets a multi-billion dollar market. Successful commercialization of BEAM-101 could validate their entire platform and unlock significant value across their broader pipeline, which includes programs for Alpha-1 Antitrypsin Deficiency (BEAM-302) and Glycogen Storage Disease Type Ia (BEAM-301).
Risk Factors: The primary risks include clinical trial setbacks, competition from other gene editing modalities (including other in vivo and established ex vivo therapies), and manufacturing challenges. While base editing is precise, unforeseen long-term side effects could still emerge. Market adoption and pricing strategies will also be critical for commercial success.
While the in vivo gene editing revolution marches forward, companies heavily invested in ex vivo gene therapies, particularly those with complex and costly manufacturing processes, face increasing pressure. bluebird bio (NASDAQ: BLUE) is a prime example of a company that could be negatively affected. With a market capitalization of approximately $48.67 million as of July 2026, bluebird bio's financial position is precarious.
bluebird bio's flagship products, like Lyfgenia for sickle cell disease, are ex vivo therapies. These treatments involve harvesting a patient's cells, genetically modifying them outside the body, and then reinfusing them. This process is inherently more complex, time-consuming, and expensive than in vivo approaches, requiring specialized facilities and patient conditioning (e.g., chemotherapy). The FDA's streamlined pathway for in vivo therapies directly threatens the competitive edge of these ex vivo modalities by making direct-to-patient treatments more accessible and potentially cheaper.
Investment Thesis: Investors should exercise extreme caution with BLUE. The company's reliance on ex vivo therapies, coupled with its small market cap and historical commercialization challenges, makes it vulnerable to the accelerating shift towards in vivo treatments. While bluebird bio has FDA-approved therapies, their commercial ramp-up has been slow, with Casgevy (a competitor ex vivo therapy from Vertex/CRISPR) only generating $116 million in 2025. The company has already ceased public trading as of June 2025, having been acquired and taken private by Carlyle and SK Capital, highlighting the significant challenges faced by its business model. This privatization further limits investor access and liquidity.
Potential Catalysts for Decline: Increased success and broader adoption of in vivo gene editing therapies, particularly for indications like SCD, would directly erode the market share and perceived value of ex vivo treatments. Any further delays or manufacturing issues with bluebird bio's existing therapies, or a failure to demonstrate superior long-term outcomes compared to emerging in vivo options, could exacerbate its struggles. The high cost and logistical hurdles associated with ex vivo treatments will continue to be a significant barrier to widespread adoption, especially as in vivo alternatives become more viable.
May your portfolios be as green as the energy we just discussed. Until next time, keep your stops tight and your research deep.
— The Vetta Research Team
Precedence Research, "Gene Therapy Market Size, Share, Trends, & Analysis Report," Precedence Research, 22 May 2024, https://www.precedenceresearch.com/gene-therapy-market. Beam Therapeutics, "Beam Therapeutics Announces Promising Initial Data from BEACON Study of BEAM-101 for Sickle Cell Disease," Beam Therapeutics Investor Relations, 2024, https://ir.beamtherapeutics.com/news-releases/news-release-details/beam-therapeutics-announces-promising-initial-data-beacon-study. U.S. Food and Drug Administration, "Guidance for Industry: Gene Therapy for Hemophilia," FDA, January 2021, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/gene-therapy-hemophilia. U.S. Food and Drug Administration, "Expedited Programs for Serious Conditions – Drugs and Biologics," FDA, May 2014, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics. Verve Therapeutics, "Verve Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update," Verve Therapeutics Investor Relations, May 2026, https://ir.vervetx.com/news-releases/news-release-details/verve-therapeutics-reports-first-quarter-2026-financial-results. Intellia Therapeutics, "Intellia Therapeutics Announces Positive Interim Data from Phase 1 Study of NTLA-2001 for ATTR Amyloidosis," Intellia Therapeutics Investor Relations, 2025, https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-positive-interim-data-phase-1. Eli Lilly and Company, "Lilly Announces Positive Top-Line Results from SURMOUNT-MMO Trial of Tirzepatide," Eli Lilly Investor Relations, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-announces-positive-top-line-results-surmount-mmo-trial. Novo Nordisk, "Wegovy® (semaglutide) receives FDA approval for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease," Novo Nordisk Press Release, March 2024, https://www.novonordisk.com/news-and-media/news-and-press-releases/news-display-page.html?id=141873.
All sources were verified at the time of publication.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Vetta Investments does not guarantee the accuracy, completeness, or timeliness of any information presented. Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Readers should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. Vetta Investments may hold positions in securities mentioned in this article.